Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required)
Funding Opportunity RFA-DK-23-011 from the NIH Guide for Grants and Contracts. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving tec...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 30, 2024 Category: Research Source Type: funding
Sodium Reduction in Communities
Funding Opportunity Number: CDC-RFA-DP16-1607 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.082Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(...
Source: Grants.gov - January 14, 2016 Category: Research Tags: Health Source Type: funding
Evalution of Iron Species in Healthy Subjects treated with Generic and Reference Sodium Ferric Gluconate
This study is part of post-market surveillance on approved generic products, which can help address potential concerns regarding the quality of generic iron complex products and support the Agencys review standards.
Detailed Descriptions:
A prospective, randomized, 2-way crossover study to compare plasma TI, TBI, NTBI levels in healthy subjects treated with generic and reference sodium ferric gluconate injections is preferred. Utilize in vitro and in vivo biomarkers such as malondialdehyde, heme-oxygenase-1 (HO-1) RNA or others to evaluate the oxidative stress and toxicity caused by generic and RLD products.
1. Colle...
Source: Grants.gov - April 18, 2014 Category: Research Tags: Health Science and Technology and other Research and Development Source Type: funding
Sodium Reduction in Communities
Funding Opportunity Number: CDC-RFA-DP13-1301 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.082Eligible Applicants Others (see text field entitled "Additional Information on Eligibility" for clarification)Agency Name: HHS-CDCClosing Date: Jun 18, 2013Award Ceiling: $250,000Expected Number of Awards: 7Creation Date: May 03, 2013Funding Opportunity Description: . The purpose of this program is to reduce sodium intake to limits recommended by the Dietary Guidelines for Americans, 2010. Because the...
Source: Grants.gov - May 6, 2013 Category: Research Tags: Health Source Type: funding
